Radioguidance based on low-energy (< 150 keV) gamma ray emitting radiopharmaceuticals is most commonly applied for sentinel lymph node (SN) biopsy procedures using (indocyanine green-)99mTc-nanocolloid [5], radioguided occult lesion localization (ROLL) procedures using 99mTc-labeled macro-aggregates [6], radioguided 125I-seed localization (RSL) procedures [7], and 99mTc-PSMA-guided resection of lymph node metastases in prostate cancer patients [3]. This evidence concerns the gene FOLH1 and metastatic malignant neoplasm in the lymph nodes.